25% Raise in 2024 UZEDY® Revenue Outlook & Key Milestone Reached for Olanzapine LAI clinical Phase 3
November 6, 2024
November 6, 2024
New Phase 3 Positive Results for Olanzapine LAI and Real-World Data on UZEDY®
November 4, 2024
November 4, 2024
New Treatment Insights into Switching to UZEDY® from Perseris®
September 23, 2024
September 23, 2024
Teva provides update on pivotal clinical Phase 3 of investigational Olanzapine LAI and UZEDY® commercial progress
July 31, 2024
July 31, 2024
Medincell’s Partner Teva presented New Data Providing Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) from Invega Sustenna® (paliperidone palmitate)
June 3, 2024
June 3, 2024
MedinCell’s partner Teva provides guidance for UZEDY in 2024 and an update on olanzapine LAI (mdc-TJK)
January 31, 2024
January 31, 2024
MedinCell’s partner Teva announces successful launch of UZEDY™
August 2, 2023
August 2, 2023
First FDA approval and US commercial launch, MedinCell enters new era
Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults
